Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Will Merck's Anti-PD-1 Therapy be the First to Launch?
Yahoo/Zacks.com
Tuesday, July 1, 2014 - 1:02pm
tags:
Merck, anti-PD-1 immunotherapy, MK-3475
Actavis represents good takeover alternative for Pfizer, says Leerink
Yahoo/Fly on the Wall
Tuesday, July 1, 2014 - 12:23pm
tags:
Pfizer, Actavis, M&A, Forest Labs, AstraZeneca
DEALTALK-Allergan readies defense as it fights Valeant for votes
Reuters
Tuesday, July 1, 2014 - 11:21am
tags:
Allergan, Valeant Pharmaceuticals, M&A
Actavis plc completes Forest Laboratories acquisition
Reuters
Tuesday, July 1, 2014 - 11:19am
tags:
Actavis, Forest Labs, M&A
Sanofi raises stake in Regeneron to 22.5 percent from 20.5 percent
Reuters
Tuesday, July 1, 2014 - 11:17am
tags:
Sanofi, Regeneron
Masimo escapes blood testing patent lawsuit
Mass Device
Tuesday, July 1, 2014 - 11:16am
tags:
Masimo, patents, devices
Did FDA Rely on Exaggerated Numbers to Justify Zohydro?
WSJ Online
Tuesday, July 1, 2014 - 11:11am
tags:
FDA, Zohydro, Zogenix
The Ugly Truth Behind Ohr Pharma
Seeking Alpha
Tuesday, July 1, 2014 - 11:08am
tags:
Ohr Pharmaceutical
Cordis launches SABER PTA Dilatation Catheter
Yahoo/Fly on the Wall
Tuesday, July 1, 2014 - 10:50am
tags:
Cordis, dilatation catheter, Saber, devices
Why Merck Should Buy Inovio, Seattle Genetics, or MannKind
Motley Fool
Tuesday, July 1, 2014 - 10:37am
tags:
Merck, M&A, Inovio, Seattle Genetics, MannKind
Agenus brain cancer vaccine nearly doubles survival rate in study
Yahoo/Reuters
Tuesday, July 1, 2014 - 10:33am
tags:
Agenus, brain cancer, vaccines, glioblastoma multiforme
Gilead Sciences and Celgene Corporation Have Great Growth Potential
Motley Fool
Tuesday, July 1, 2014 - 10:31am
tags:
Celgene, Gilead Sciences, Revlimid, Sovaldi
Physicians Interactive CEO Looks for Acquisitions
TheStreet.com
Tuesday, July 1, 2014 - 10:23am
tags:
Merck, venture capital, M&A, Physicians Interactive
Shire CEO's buyout plans thwarted when AbbVie came calling
Fierce Pharma
Monday, June 30, 2014 - 5:59pm
tags:
Shire, AbbVie, Flemming Ornskov
Bluebird Bio acquires Precision Genome Engineering
The Fly on the Wall
Monday, June 30, 2014 - 5:58pm
tags:
Bluebird Bio, M&A, Precision Genome Engineering
Why Teva's Magic Bullet Could Misfire
Motley Fool
Monday, June 30, 2014 - 5:57pm
tags:
Teva Pharmaceuticals, Copaxone, MS, multiple sclerosis
Biogen Hemophilia Drugs Launch Into The Unknown
Investors.com
Monday, June 30, 2014 - 5:53pm
tags:
Biogen Idec, hemophilia, Alprolix, Eloctate
MannKind's Afrezza Approved but Will Doctors Prescribe It?
Motley Fool
Monday, June 30, 2014 - 5:45pm
tags:
MannKind, Afrezza, insulin, diabetes, inhaled insulin
1 Critical Question Swirling Around Medtronic's Mega-Merger
Motley Fool
Monday, June 30, 2014 - 5:44pm
tags:
M&A, Covidien, devices, Medtronic
Gilead Seeks Japanese Approval for Sovaldi
Yahoo/Zacks.com
Monday, June 30, 2014 - 5:43pm
tags:
Japan, hepatitis C, Sovaldi, Gilead Sciences

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.